These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Trial of combination chemotherapy for multiple myeloma and macroglobulinemia--VENAP therapy (author's transl)]. Furukawa K; Fujiwara Y; Nakaide Y; Tanaka M; Tanaka M; Hirota Y Rinsho Ketsueki; 1980 Nov; 21(11):1683-91. PubMed ID: 6782278 [No Abstract] [Full Text] [Related]
5. [Chemotherapy of multiple myeloma. Review of the recent trials]. Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807 [No Abstract] [Full Text] [Related]
6. Treatment of multiple myeloma and macroglobulinemai Waldenström: A long-term follow-up study. Onodera S; Otaki M; Oikawa K; Mikami M; Sato I Tohoku J Exp Med; 1975 Aug; 116(4):317-25. PubMed ID: 810919 [TBL] [Abstract][Full Text] [Related]
7. [Recent progress in chemotherapy of multiple myeloma]. Tortarolo M; Cantore N; Russolillo S; Castaldo C; Buonanno G Recenti Prog Med; 1978 Jul; 65(1):44-68. PubMed ID: 370935 [No Abstract] [Full Text] [Related]
8. [Therapy of paraproteinemic hemoblastoses]. Fereberger W Acta Med Austriaca; 1982; 9(4):151-7. PubMed ID: 6814158 [TBL] [Abstract][Full Text] [Related]
9. [Results of plasmacytoma therapy of ALGB (acute leukemia group B)]. Obrecht JP Hamatol Bluttransfus; 1976; 18():383-93. PubMed ID: 964714 [No Abstract] [Full Text] [Related]
10. [Therapy of hemoblastoses. V. Plasmocytoma and macroglobulinemic reticulosis of Walderström]. Danieli G G Clin Med; 1967 Feb; 48(2):164-74. PubMed ID: 4971622 [No Abstract] [Full Text] [Related]
11. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma. Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H; Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of mouse myeloma: quantitative cell cultures predictive of response in vivo. Ogawa M; Bergsagel DE; McCulloch EA Blood; 1973 Jan; 41(1):7-15. PubMed ID: 4682084 [No Abstract] [Full Text] [Related]
13. An overview of the status of the nitrosoureas in other tumors. Carter SK Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034 [No Abstract] [Full Text] [Related]
14. [Non-secreting myeloma with myelomatous kidney. A case of parciall resistance to melphalen and cyclophosphamide with favorable response to nitrosourea combination]. Peña Yáñez A; Bermúdez JM; Raya J; Salmerón J; Palomo S Rev Clin Esp; 1976 Dec; 143(6):543-50. PubMed ID: 796906 [No Abstract] [Full Text] [Related]
15. Clinical utilization of plasmapheresis and cyclophosphamide in the treatment of malignant lymphoproliferative processes. Sakalová A; Gazová S; Hrubisko M; Gáliková J Neoplasma; 1973; 20(3):335-9. PubMed ID: 4199115 [No Abstract] [Full Text] [Related]
16. [Combined cytostatic therapy of plasmacytoma]. Albert P; Zsuzsa M Orv Hetil; 1977 Jul; 118(31):1855-6. PubMed ID: 887257 [No Abstract] [Full Text] [Related]